Characterization of different high molecular weight angiotensinogen forms

American Journal of Hypertension

Volumn 16, Issue 6, 2003, Pages 478-483

  Ramaha, Ahmed ^a   Célérier, Jérôme ^b   Patston, Philip A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Centre de Recherche Interdisciplinaire en Biologie   (France)

Author keywords

Angiotensinogen; Angiotensinogen polymers; High molecular weight angiotensinogen; Serpin

Indexed keywords

ANGIOTENSINOGEN; DODECYL SULFATE SODIUM;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; FEMALE; GEL FILTRATION; HUMAN; IN VITRO STUDY; ION EXCHANGE CHROMATOGRAPHY; MALE; MOLECULAR WEIGHT; NORMAL HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN POLYMERIZATION; PROTEIN PURIFICATION; WESTERN BLOTTING;

EID: 0037528713     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)00053-0     Document Type: Article

References (30)

1. Campbell CJ, Charlton PA, Grinham CJ, Mooney CJ, Pendlebury JE: The rapid purification and partial characterization of human serum angiotensinogen. Biochem J 1987;243:121-126.
2. Gordon DB, Sachin IN: Chromatographic separation of multiple renin substrates in women; effect of pregnancy and oral contraceptives. Proc Soc Exp Biol Med 1977;156:461-464.
3. Tewksbury DA, Dart RA: High molecular weight angiotensinogen levels in hypertensive pregnant women. Hypertension 1982;4:729-734.
4. Tetlow HJ, Broughton Pipkin F: Changing renin substrates in human pregnancy. J Endocrinol 1986;109:257-262.
5. Tewksbury DA: Quantitation of five forms of high molecular weight angiotensinogen from human placenta. Am J Hypertens 1996;9:1029-1034.
6. Tewksbury DA, Goodman JR, Kaiser SJ, Burrill RE, Brown HL: Quantitation of five forms of plasma high molecular weight angiotensinogen in women with pregnancy-induced hypertension. Am J Hypertens 2000;13:221-225.
7. Tewksbury DA, Tryon ES, Burrill RE, Dart RA: High molecular weight angiotensinogen: A pregnancy associated protein. Clinica Chimica Acta 1986;158:7-12.
8. Tewksbury DA, Tryon ES: Immunochemical comparison of high molecular weight angiotensinogen from amniotic fluid, plasma of men, and plasma of pregnant women. Am J Hypertens 1989;2:411-413.
9. Oxvig C, Haaning J, Kristensen L, Wagner JM, Rubin I, Stigbrand T, Gleich GJ, Sottrup-Jensen L: Identification of angiotensinogen and complement C3dg as novel proteins binding the eosinophil major basic protein in human pregnancy serum and plasma. J Biol Chem 1995;270:13645-13651.
10. Christiansen M, Jaliashvili I, Overgaard MT, Ensinger C, Obrist P, Oxvig C: Quantification and characterization of pregnancy-associated complexes of angiotensinogen and the proform of eosinophil major basic protein in serum and amniotic fluid. Clin Chem 2000;46:1099-1105.
11. Gimenez-Roqueplo AP, Célérier J, Schmidt G, Corvol P, Jeunemaitre X: Role of cysteine residues in human angiotensinogen. Cys232 is required for angiotensinogen-pro major basic protein complex formation. J Biol Chem 1998;273:34480-34487.
12. Shionoiri H, Eggena P, Barrett JD, Thananopvarn C, Golub MS, Eggena Z, Nakamura R, Judd HL, Sambhi MP: An increase in high-molecular weight renin substrate associated with estrogenic hypertension. Biochem Med 1983;29:14-22.
13. Shionoiri H, Gotoh E, Kaneko Y, Eggena P, Sambhi MP: Differences in the kinetic rate constants of normal and high molecular weight renin substrate from term pregnancy human plasma. Endocrinol Japan 1983;30:731-736.
14. Tryon ES, Tewksbury DA: Kinetic analysis of the reaction of human renin with human high and low molecular weight angiotensinogen. Hypertens Pregn 1995;14:327-338.
15. Sato Y, Hiwada K, Kokubo T: Physicochemical characteristics of human high molecular weight angiotensinogen. Life Sci 1985;37:371-377.
16. Tewksbury DA, Kaiser SJ, Burrill RE: A study of the temporal relationship between plasma high molecular weight angiotensinogen and the development of pregnancy-induced hypertension. Am J Hypertens 2001;14:794-797.
17. Stein PE, Tewksbury DA, Carrell RW: Ovalbumin and angiotensinogen lack S-R conformational change. Biochem J 1989;262:103-107.
18. Huber R, Carrell RW: Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 1989;28:8951-8966.
19. Streatfeild-James RMA, Williamson D, Pike RN, Tewksbury D, Carrell RW, Coughlin PB: Angiotensinogen cleavage by renin: importance of a structurally constrained N-terminus. FEBS Lett 1998;436:267-270.
20. Célérier J, Schmidt G, Le Caer J-P, Gimenez-Roqueplo AP, Bur D, Friedlein A, Langen H, Corvol P, Jeunemaitre X: Characterization of a human angiotensinogen cleaved in its reactive center loop by a proteolytic activity from Chinese hamster ovary cells. J Biol Chem 2000;275:10648-10654.
21. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA Remold-, O'Donnell E, Salvesen GS, Travis J, Whisstock JC: The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001;276:33293-33306.
22. Patston PA, Hauert J, Michaud M, Schapira M: Formation and properties of C1-inhibitor polymers. FEBS Lett 1995;368:401-404.
23. Suda S, Gettins PGW, Patston PA: Linkage between the hormone binding site and the reactive center loop of thyroxine binding globulin. Arch Biochem Biophys 2000;384:31-36.
24. 1 proteinase inhibitor probed by intrinsic tryptophan fluorescence spectroscopy. Protein Sci 1996;5:2226-2235.
25. 1-Antitrypsin polymerisation can occur by both loop A and C sheet mechanisms. Biochem Biophys Res Commun 1998;251:1-5.
26. Chang WSW, Whisstock J, Hopkins PCR, Lesk AM, Carrell RW, Wardell MR: Importance of the release of strand 1C to the polymerization mechanism of inhibitory serpins. Protein Sci 1997;6:89-98.
27. Zhou A, Huntington JA, Carrell RW: Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999;94:3388-3396.
28. Fitton HL, Pike RN, Carrell RW, Chang WS: Mechanisms of antithrombin polymerisation and heparin activation by insertion of synthetic reactive loop peptides. Biol Chem 1997;378:1059-1063.
29. Overgaard MT, Haaning J, Boldt HB, Olsen IM, Laursen LS, Christiansen M, Gleich GJ, Sottrup-Jensen L, Conover CA, Oxvig C: Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor. J Biol Chem 2000;275:31128-31133.
30. Célérier J, Cruz A, Lamande N, Gasc JM, Corvol P: Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension 2002;39:224-228.